New drug combo aims to keep myeloma in check after transplant
NCT ID NCT03346135
First seen Dec 15, 2025 · Last updated May 14, 2026 · Updated 20 times
Summary
This study tests whether the drug daratumumab, given after a stem cell transplant, can help keep multiple myeloma from coming back. About 31 participants will receive daratumumab as a follow-up treatment. The goal is to see if it improves how long people live without their cancer worsening and reduces any remaining cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Sarah Cannon Cancer Center
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.